ticlopidina normon efg 250 mg 500 comprimits
ticlopidina alter 250mg 50 comprimidos recubiertos pelicula efg
ticlopidina normon 250mg 50 comprimidos recub efg
ticlopidina cinfa 250mg 50 comp recub efg
ticlopidina normon efg 250 mg 20 comprimits
clopi-denk 75
artesan pharma gmbh & co. kg - clopidogrel (clopidogrel besylate) - tablets film-coated - 75mg
tiklid 250 mg 50 comprimits
teva-ticlopidine tablet
teva canada limited - ticlopidine hydrochloride - tablet - 250mg - ticlopidine hydrochloride 250mg - platelet aggregation inhibitors
ticlopidine hydrochloride- ticlopidine hydrochloride tablet, film coated
eon labs, inc. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - ticlopidine hydrochloride tablets are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see box warning and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic anemia - presence of a hemostatic disorder or active